Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.81B +132.8% |
| Revenue (ttm) | 71.78M +27.2% |
| Net Income | -295.28M |
| EPS | -3.17 |
| Shares Out | 103.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 831,495 |
| Open | 17.46 |
| Previous Close | 17.38 |
| Day's Range | 17.08 - 18.10 |
| 52-Week Range | 8.20 - 22.50 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 30.18 (+72.75%) |
| Earnings Date | Jul 8, 2026 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical tr... [Read more]
Financial Performance
In fiscal year 2025, Nurix Therapeutics's revenue was $83.98 million, an increase of 53.95% compared to the previous year's $54.55 million. Losses were -$264.46 million, 36.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $30.18, which is an increase of 72.75% from the latest price.
News
Nurix Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
BTK degraders demonstrate high efficacy and durability in CLL, with bexobrutideg showing best-in-class potential and advancing through pivotal trials. Expansion into autoimmune and neurology indications is underway, supported by strong preclinical and early clinical data. Partnerships with Gilead and Sanofi further diversify the pipeline.
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteer...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther...
Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Lead BTK degrader is advancing to phase III for CLL, showing strong efficacy and safety, with a new confirmatory trial against pirtobrutinib. Autoimmune and early-stage programs are progressing, and the company is well-funded with $650M in cash.
Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo
Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $29 and keeps an Overweight rating on the shares. While management continues to execute on bexdeg’s…
Nurix Therapeutics price target lowered to $34 from $35 at Stifel
Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $35 and keeps a Buy rating on the shares after the company reported a GAAP net loss…
Nurix Therapeutics reports Q1 EPS (79c), consensus (76c)
Reports Q1 revenue $6.3M, consensus $14.24M. Cash, cash equivalents and marketable securities were $540.7M as of February 28, 2026, compared to $592.9M as of November 30, 2025. “Nurix entered 2026…
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Nurix Therapeutics Earnings release: Q1 2026
Nurix Therapeutics released its Q1 2026 earnings on April 8, 2026, summarizing the period's financial results.
Nurix Therapeutics Quarterly report: Q1 2026
Nurix Therapeutics has published its Q1 2026 quarterly earnings report on April 8, 2026.
Nurix Therapeutics to Participate in Upcoming Investor Conference
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Proxy statement: Proxy filing
Nurix Therapeutics filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Nurix Therapeutics Proxy statement: Proxy filing
Nurix Therapeutics filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium
Degrader therapies in immunology offer advantages over inhibitors by eliminating entire protein functions, enabling targeting of challenging proteins like STAT6. Key programs, including STAT6 (with Sanofi), BTK, and IRAK4 (with Gilead), are advancing, with major clinical milestones expected this year.
Nurix Therapeutics price target raised to $35 from $33 at Stifel
Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $33 and keeps a Buy rating on the shares following the Q4 report. The firm continues to…
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Nurix Therapeutics (NRIX) to $29 from $30 and keeps an Overweight rating on the shares. While there are not…
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler
Piper Sandler raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $32 and keeps an Overweight rating on the shares following quarterly results and pipeline update. The…
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $31 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)
Reports Q4 revenue $13.6M, consensus $13.41M. “The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak registrational program for bexobrutideg and strengthened our ...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile i...
Nurix Therapeutics Annual report: Q4 2025
Nurix Therapeutics has published its Q4 2025 annual report on January 28, 2026.
Nurix Therapeutics Earnings release: Q4 2025
Nurix Therapeutics released its Q4 2025 earnings on January 28, 2026, summarizing the period's financial results.